Combination therapies in multiple sclerosis

Journal of Neurology

Volumn 255, Issue SUPPL. 1, 2008, Pages 51-60

  Gold, Ralf ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

Beta interferon; Combination therapy; Experimental autoimmune encephalomyelitis; Glatiramer acetate; Multiple sclerosis

Indexed keywords

ATORVASTATIN; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; MINOCYCLINE; MITOXANTRONE; NATALIZUMAB; PLACEBO; SIMVASTATIN;

ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; BLOOD TOXICITY; CARDIOTOXICITY; CHOLESTEROL METABOLISM; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERCHOLESTEROLEMIA; MONOTHERAPY; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PEPTIDES;

EID: 40349096094     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-008-1008-2     Document Type: Conference Paper

References (45)

1. Arnold D, Amit Bar-Or A, Freedman M, Gazda S, Panitch H, Vollmer T (2007) Reductions in Gd Enhancing Lesions Observed with Glatiramer Acetate Following a Brief and Low Dose Course of Mitoxantrone in Patients with Relapsing Remitting Multiple Sclerosis (RRMS) Are Paralleled by Favorable Effects on MRI Markers of Disease Burden and Black Hole Evolution. Neurology 68(Suppl 1):A281
2. Bar-Or A, Gibbs E, Niino M, Aziz T, Alatab S, Shi F, Campagnolo D, Jalili F, Rhodes S, Yamashita T, Fan B, Freedman M, Panitch H, Arnold D, Vollmer T, Oger J (2007) Tracking In Vivo Immune Modulation in MS Patients Treated with Glatiramer Acetate (GA) Alone, or with GA Preceded by Mitoxantrone, Provides Novel Insights into the Mode of Action of Therapeutic Strategies That Combine Immune Suppression and Immune Deviation. Neurology 68(Suppl 1):A18
3. Birnbaum G, Altafullah I, Reder R (2007) A Double Blind, Placebo Controlled Trial of Atorvastatin in Combination with Subcutaneous Interferon Beta 1a in Persons with Multiple Sclerosis. Neurology 68(Suppl 1):A206-A207
4. Bradbury J (2006) Atorvastatin and glatiramer acetate: new hope in MS? Lancet Neurology 5:386-387
5. Brod SA, Lindsey JW, Wolinsky JS (2000) Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitis. Ann Neurol 47:127-131
6. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW (2002) Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 125:1297-1308
7. Chan A, Weilbach FX, Toyka KV, Gold R (2005) Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol 139:152-158
8. Dhib-Jalbut S, Chen M, Henschel K, Ford D, Costello K, Panitch H (2002) Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis. Mult Scler (Houndmills, Basingstoke, England) 8:485-491
9. Edan G, Miller D, Clanet M, Confavreux C, Lyon-Caen O, Lubetzki C, Brochet B, Berry I, Rolland Y, Froment JC, Cabanis E, Iba-Zizen MT, Gandon JM, Lai HM, Moseley I, Sabouraud O (1997) Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62:112-118
10. Emery P (2006) Treatment of rheumatoid arthritis. BMJ Clin Res ed 332:152-155
11. Fox EJ (2004) Mechanism of action of mitoxantrone. Neurology 63:S15-S18
12. Giuliani F, Metz LM, Wilson T, Fan Y, Bar-Or A, Yong VW (2005) Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J Neuroimmunol 158:213-221
13. Gold R, Linington C, Lassmann H (2006) Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129:1953-1971
14. Golub LM, Ramamurthy N, McNamara TF, Gomes B, Wolff M, Casino A, Kapoor A, Zambon J, Ciancio S, Schneir M, et al. (1984) Tetracyclines inhibit tissue collagenase activity. A new mechanism in the treatment of periodontal disease. J Periodontal Res 19:651-655
15. Gonsette RE (1996) Mitoxantrone immunotherapy in multiple sclerosis. Mult Scler (Houndmills, Basingstoke, England) 1:329-332
16. Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360:2018-2025
17. Havrdova E, Zivadinov R, Krasensky J, Dwyer M, Novakova I, Dolezal O, Ticha V, Svobodnik A, Seidl Z, Houzvickova E, Horakova D (2007) Intramuscular Interferon Beta-1a, Azathioprine, and Corticosteroid Combination Therapy in Patients with Relapsing-Remitting Multiple Sclerosis: 5-Year Clinical Efficacy Results. Neurology 68(Suppl 1):A277
18. Ifergan I, Wosik K, Cayrol R, Kebir H, Auger C, Bernard M, Bouthillier A, Moumdjian R, Duquette P, Prat A (2006) Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann Neurol 60:45-55
19. Kieseier BC, Archelos JJ, Hartung HP (2004) Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases. Arch Neurol 61:929-932
20. Lublin F, Cutter G, Elfont R, Khan O, Lisak L, McFarland H, Panitch H, Noseworthy J, Reingold S, Whitaker J, Wolinsky J, Baier M, Weber M (2001) A trial to assess the safety of combining therapy with interferon beta-1a and glatiramer acetate in patients with relapsing MS. Neurology 56(Suppl. 3):A148
21. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707-717
22. Lus G, Romano F, Scuotto A, Accardo C, Cotrufo R (2004) Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment. Eur Neurol 51:15-20
23. Metz L, Li D, Traboulsee A, Myles M, Duquette P, Godin J, Constantin M, Yong V (2007) Glatiramer acetate combined with minocycline reduces the number of T1 Gd-enhancing and new T2 lesions compared to glatiramer actetate alone. Neurology 68(Suppl 1):A84-A85
24. Metz LM, Zhang Y, Yeung M, Patry DG, Bell RB, Stoian CA, Yong VW, Patten SB, Duquette P, Antel JP, Mitchell JR (2004) Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 55:756
25. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG), Rieckmann P (2006) Immunmodulatorische Stufentherapie der Multiplen Sklerose. Der Nervenarzt 77:1506-1518
26. Neuhaus O, Kieseier BC, Hartung HP (2004) Mechanisms of mitoxantrone in multiple sclerosis - what is known? J Neurol Sci 223:25-27
27. Neuhaus O, Strasser-Fuchs S, Fazekas F, Kieseier BC, Niederwieser G, Hartung HP, Archelos JJ (2002) Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 59:990-997
28. Neuhaus O, Wiendl H, Kieseier BC, Archelos JJ, Hemmer B, Stuve O, Hartung HP (2005) Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro. J Neuroimmunol 168:128-137
29. Paemen L, Martens E, Norga K, Masure S, Roets E, Hoogmartens J, Opdenakker G (1996) The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. Biochem Pharmacol 52:105-111
30. Patel AA, Swerlick RA, McCall CO (2006) Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol 55:369-389
31. Peng X, Jin J, Giri S, Montes M, Sujkowski D, Tang Y, Smrtka J, Vollmer T, Singh I, Markovic-Plese S (2006) Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis. J Neuroimmunol 178:130-139
32. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899-910
33. Prinz M, Schmidt H, Detje C, Mildner A, Knobeloch K, Hanisch U, Gold R, Becher B, Brück W, Kalinke U (2006) Type 1 interferon receptor (IFNAR)-dependent modulation of myeloid cell activation determines the course of experimental autoimmune encephalomyelitis. Mult Scler 12(Suppl 1):S52
34. Pulicken M, Bash CN, Costello K, Said A, Cuffari C, Wilterdink JL, Rogg JM, Mills P, Calabresi PA (2005) Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis. Mult Scler (Houndmills, Basingstoke, England) 11:169-174
35. Ramtahal J, Jacob A, Das K, Boggild M (2006) Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. J Neurol 253:1160-1164
36. Ridge SC, Sloboda AE, McReynolds RA, Levine S, Oronsky AL, Kerwar SS (1985) Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clin Immunol Immunopathol 35:35-42
37. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911-923
38. Stanislaus R, Singh AK, Singh I (2001) Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. J Neurosci Res 66:155-162
39. Stuve O, Youssef S, Weber MS, Nessler S, von Budingen HC, Hemmer B, Prod'homme T, Sobel RA, Steinman L, Zamvil SS (2006) Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 116:1037-1044
40. Vollmer T, Campagnolo D, Panitch P, Bar-Or A, Arnold D (2007) Reductions in MRI Disease Activity and Relapse Rates Observed after Induction of Shortterm Immunosuppression with Mitoxantrone Followed by Longterm Glatiramer Acetate (GA) Are Maintained at 24 Months in Patients with Relapsing Remitting Multiple Sclerosis (RRMS). Neurology 68(Suppl 1):A279
41. Yong VW, Chabot S, Stuve O, Williams G (1998) Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 51:682-689
42. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420:78-84
43. Zamvil SS, Steinman L (2002) Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS. Neurology 59:970-971
44. Zhang J, Hutton G, Zang Y (2002) A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis. Clinical Therapeutics 24:1998-2021
45. Ziemssen T, Schrempf W (2007) Glatiramer acetate: mechanisms of action in multiple sclerosis. Int Rev Neurobiol 79:537-570